AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$5.00
+$0.01 (+0.22%) 4:00 PM ET
Prev closePrevC$4.99
OpenOpen$4.95
Day highHigh$5.09
Day lowLow$4.92
VolumeVol805,511
Avg volAvgVol1,106,704
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$322.20M
P/E ratio
-2.79
EPS
-1.79
Sector
Healthcare
AI report sections
MIXED
IMRX
Immuneering Corporation
No AI report section text found yet for this symbol.
U.S. stock futures declined on Thursday with investors awaiting Supreme Court ruling on tariffs and December jobs reports. AZZ surged on strong earnings, Northrop Grumman jumped on defense spending proposals, while Immuneering tumbled on disappointing trial data and Phathom dropped following stock offering announcement. Constellation Brands rose on better-than-expected earnings.
Stock tumbled 22.93% after announcing updated Phase 2a trial data for pancreatic cancer treatment, indicating disappointing clinical results.
PositiveGlobeNewswire Inc.• Na
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
Immuneering Corporation announced positive Phase 2a trial results showing 64% overall survival at 12 months for atebimetinib combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, nearly double the 35% benchmark from standard of care. The company plans to initiate its pivotal Phase 3 trial (MAPKeeper 301) in mid-2026, with FDA and EMA alignment already secured on trial design.
The company reported exceptional clinical trial results with 64% 12-month overall survival, nearly double the standard of care benchmark of 35%. The drug demonstrated consistent survival advantages across multiple time points (6, 9, and 12 months), favorable tolerability profile, and the company has secured regulatory alignment for a pivotal Phase 3 trial expected to begin mid-2026, representing significant clinical and commercial progress.
PositiveBenzinga• Globe Newswire
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
Immuneering Corporation will host a conference call to discuss updated overall survival and safety data from a Phase 2a clinical trial of atebimetinib + mGnP in first-line pancreatic cancer patients, with 9 months median follow-up.
Company is presenting promising clinical trial results for a potential cancer treatment, highlighting potential advancement in pancreatic cancer therapy
PositiveBenzinga• Avi Kapoor
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket
PepGen Inc. experienced a significant 112.4% pre-market stock surge after announcing an underwritten public offering of common stock and pre-funded warrants. Several other stocks showed notable pre-market movements, with some gaining and others declining.
Rose 30% after announcing $175 million public offering and $25 million private placement with Sanofi
PositiveGlobeNewswire Inc.• Carson Creehan
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
Immuneering Corporation announced a public offering of 18,959,914 Class A common stock shares at $9.23 per share, raising approximately $175 million. Simultaneously, Sanofi will purchase 2,708,559 shares in a private placement transaction.
Raising significant capital ($175M) to advance preclinical and clinical development of product candidates indicates strong growth strategy and financial health
PositiveGlobeNewswire Inc.• Ben Zeskind, Ph.D.
Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
Immuneering plans to share updated overall survival data for atebimetinib + mGnP in first-line pancreatic cancer patients, with presentations at investor call and scientific conferences highlighting promising early results.
Company reported exceptional 94% overall survival at 6 months, significantly higher than standard of care, and is presenting promising clinical trial data across multiple conferences
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
Immuneering reported positive data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-Paclitaxel (mGnP) for first-line pancreatic cancer patients, including 94% overall survival at 6 months and a favorable tolerability profile.
The article reports positive data from Immuneering's ongoing Phase 2a trial of its lead product candidate, atebimetinib, in first-line pancreatic cancer patients, including high overall survival rates and a favorable tolerability profile. This suggests Immuneering's drug has the potential to be a more effective and better-tolerated treatment option for this patient population.
PositiveGlobeNewswire Inc.• N/A
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
Immuneering Corporation announced that it will host a conference call to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients.
IMRXImmuneering CorporationIMM-1-104Phase 2a clinical trialpancreatic cancer
Sentiment note
The article highlights Immuneering's progress in its clinical trial for IMM-1-104 in pancreatic cancer, which suggests the company is making advancements in its oncology pipeline.
PositiveGlobeNewswire Inc.• N/A
Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
Immuneering Corporation, a clinical-stage oncology company, announced that it will present at the 24th Annual Needham Virtual Healthcare Conference to discuss its pipeline, platform, and business strategy.
The article highlights Immuneering's upcoming presentation at a major healthcare conference, which suggests the company is actively engaged in advancing its oncology pipeline and business strategy.
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
IMRXClinical Study
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
